To test whether the prognostic definition of chronic pain, which has previously been applied in specific anatomic areas, performed well in a cohort of older adults with a range of musculoskeletal pain sites.
C hronic pain is typically defined by duration, an approach that has often been criticized as being unhelpful in terms of the attitudes of patients and clinicians towards chronic pain [1] [2] [3] and the implications this has for the development of treatment. 4 Using a latent transition regression model, Von Korff and Miglioretti 1 developed a prognostic approach to the definition of chronic low-back pain (LBP). This approach uses a Risk Score constructed from a small number of pain severity and prognosis-related (depression, pain duration, diffuse nature of pain) items. These items were chosen, as they had previously been shown to have prognostic value in predicting pain outcomes. 1 The Risk Score was shown to predict the likelihood of significant pain 1 year later in a group of LBP primarycare consulters in the United States. The Risk Score moves away from defining chronic pain as a static state, which it is not, 5 and towards a prognostic definition of chronicity.
Recently, the Risk Score approach has been applied, and performed well, in a group of LBP patients in the United Kingdom, 4 in American patients with LBP, headache, and orofacial pain, 3 and in a community sample in the United Kingdom reporting knee pain. 6 This suggests the prognostic value of Von Korff and Miglioretti's Risk Score under a range of pain conditions, across a number of anatomic sites. 3, 4, 6 It is known that patients experiencing pain want to know their expected prognosis 2, 7 and the Risk Score approach has been shown to have a stronger prognostic ability than considering the duration of pain alone. 3 It therefore presents a potential method by which prognostic estimates could be calculated accurately in a clinical setting.
It is reasonable to assume that this model for the prognosis of pain will perform well in the setting of generic musculoskeletal pain, that is, the model is not specific to the site of pain, or the underlying cause of pain, but performs well in evaluating the prognosis of any reported musculoskeletal pain. Further evidence of this potential was provided in a systematic review of prognostic factors for chronic musculoskeletal pain, which identified many of the same factors used in the Risk Score. 8 The aim of this paper was then to assess the performance of the Von Korff and Miglioretti 1 model in the definition of chronic pain in an older population with musculoskeletal pain across a broad range of anatomic sites over a 12-month period.
MATERIALS AND METHODS

Setting and Sample
The data come from the Prognostic Research (PROG-RES) Study, a prospective cohort of older adults consulting with musculoskeletal pain in primary care. Full details of this study have been described previously. 9 
Data Collection
During a routine, patient-initiated consultation, electronic templates were activated when one of a prespecified list of musculoskeletal Read codes was entered by the GP, leaving a marker in the patient's record. Read codes are a coded thesaurus of clinical terms used in UK GP. 10 Using these Read codes, GPs record symptoms, diagnoses, procedures, and investigations in the electronic medical record. Patients whose GP had completed the template were identified weekly by staff from the Keele General Practice Research Partnership. All such patients were sent a postal questionnaire within 1 week of consultation. This questionnaire contained further questions on pain, including the Chronic Pain Grade (CPG), 11 depression, assessed by the Hospital Anxiety and Depression Scale (HADS), 12 and information on sociodemographic characteristics. The questionnaire asked for written informed consent to both medical record review and further contact. The people who did not respond to the initial questionnaire within 2 weeks received a reminder postcard. After a further 2 weeks, nonresponders received a reminder letter and a second copy of the questionnaire. The participants consenting to further contact received a further postal questionnaire, similar to that used at baseline, 12 months later.
Risk Score
Following the same procedures as Dunn et al 4 and Thomas et al, 6 the scoring mechanism below was used to calculate the Risk Score for each individual, on the basis of the score developed by Von Korff and Miglioretti. 1 Average pain intensity: 0 to 3 = 0; 4 to 6 = 1; 7 to 10 = 2. Worst pain intensity: 0 to 4 = 0; 5 to 7 = 1; 8 to 10 = 2. Current pain intensity: 0 to 2 = 0; 3 to 4 = 1; 5 to 10 = 2. Interference with usual activities: 0 to 2 = 0; 3 to 4 = 1; 5 to 10 = 2. Interference with work/household activities: 0 to 2 = 0; 3 to 4 = 1; 5 to 10 = 2. Interference with family/social activities: 0 to 2 = 0; 3 to 4 = 1; 5 to 10 = 2. In the baseline questionnaire, participants were asked to report the areas in which they had pain from a prespecified list of 8 discrete sites (neck, shoulder, elbow, wrist/ hand, low back, hip, knee, ankle/foot). From this, the number of pain sites additional to the "index site" was calculated as the number of areas in which pain was reported, from 8, À 1. This was then categorized, as shown above.
The possible range for the Risk Score is 0 (lowest risk) to 27 (highest risk). This is one less than the highest total Risk Score proposed by Von Korff and Miglioretti, 1 because the PROG-RES Study considered activity limitation in the previous 3 months on 4 levels rather than the 5 considered in the original paper.
Outcome
As in all previous work on this prognostic method of defining chronic pain, 1,3,4,6 the definition of clinically significant pain, that is, a poor outcome, at follow-up was a CPGZII.
Statistical Methods
People who triggered the template, baseline responders, and 12-month responders were compared on the basis of age, sex, and pain characteristics to assess the potential for response bias. After calculating the Risk Score for all individuals, the same methods as Dunn et al 4 were applied to the current dataset to calculate (1) the proportion of people falling into each Risk Score group at baseline, (2) the proportion in each of the baseline Risk Score groups completing the 12-month follow-up, and (3) the proportion in each of the baseline Risk Score groups with clinically significant pain, that is, a CPGZII, at the 12-month follow-up. Second, the discriminative ability (using the area under the receiver-operating characteristic curve, and associated 95% confidence interval) and the calibration (using the Hosmer-Lemeshow test 13 ) of the Risk Score in predicting the outcome at the 12-month follow-up were assessed. Third, the method proposed by Von Korff and Miglioretti 1 was applied to identify cutoffs for possible and probable chronic pain, specific to the PROG-RES Study dataset. A binary logistic model was fitted to determine the predicted probabilities of outcome and a plot, smoothed using a 5-point rolling average, was used to display these probabilities. The new cutoffs were set to represent 50% and 80% probability of a poor outcome, respectively. Ethical approval for this study was gained from the Central Cheshire Local Research Ethics Committee (REC Reference Number: 06/Q1503/60).
RESULTS
Response and Follow-up
Electronic templates were triggered for 650 patients, of whom 502 (77%) responded to the baseline questionnaire. Responders were more likely to be female and slightly younger than nonresponders ( Table 1 ). The majority of baseline responders reported pain that had been present for Z6 months and 86% had a CPGZII. There was some attrition from the sample over the 12 months of follow-up. Those who remained in the sample (n = 329) were similar to the baseline cohort in terms of sex, baseline CPG, chronicity of pain, and anxiety and depression scores. They were, however, slightly older. The most commonly affected pain sites were the low back (29%), shoulder (27%), and knee (26%). This was similar in those who were and were not followed up for 12 months (data not shown).
Baseline Risk Scores
Of the 502 responders at baseline, 406 provided information on all Risk Score components and 262 remained in the study, providing CPG data at 12 months. In this group, the mean Risk Score at baseline was 12.2 (SD, 4.7). Using the cutoffs for the groupings of the Risk Score from the original US study, 1 more than half of the sample was in the intermediate Risk Score group ( Table 2) .
Distribution of CPG Over Time
There was a downward shift in the distribution of CPGs from baseline to 12-the month follow-up, with grade 0 increasing from 0.2% to 11.5% and grade IV decreasing from 39.4% to 24.0%.
Association Between the Baseline Risk Score Group (Von Korff and Miglioretti 1 Method) and CPG Over Time
Of the 6 patients identified as probable cases of chronic pain at baseline and providing CPG data at the 12-month follow-up, all had a CPGZII ( Table 2 ). In accordance with the definition of "possible chronic pain cases" at baseline, up to 80% would be expected to have a CPGZII at follow-up; this was exceeded in the PROG-RES Study dataset (86%). Similarly, between 20% and 50% of the patients with an intermediate risk of chronic pain at baseline would be expected to have a CPGZII at 12 months; this was 50% in the PROG-RES Study sample. In those patients classified as low risk at baseline, up to 20% would be expected to have significant pain at 12-months 
Model Performance
Calibration of the Risk Score in predicting significant pain at the 12-month follow-up was good (Hosmer-Lemeshow w 2 = 15.68, P-value = 0.8314). The area under the curve was high at 0.79 (95% confidence interval, 0.74, 0.85).
Baseline Risk Score Groups (Defined in the Current Dataset) and Chronic Pain Over Time
The increasing proportion of people with significant pain in each risk group, as defined by Von Korff and Miglioretti, 1 and the examination of the model performance suggests that the Risk Score indeed predicts the risk of persistent pain in the PROG-RES Study sample. However, there are higher levels of significant pain at follow-up in this older sample than would be predicted by the original groupings of the Risk Score, thus suggesting that the cutoffs to define differing probabilities of outcome in the current study are different from those derived in the original US LBP sample. Figure 1 shows the probability of clinically significant pain at the 12-month follow-up according to the baseline Risk Score. At a score of r5, there is <20% probability of significant pain at the 12-month follow-up. At scores below 12, the risk at follow-up is <50%, whereas at scores <16, there is <80% probability of significant pain after 12 months. Applying these cut-points (ie, low risk = 0 to 5, intermediate risk = 6 to 11, possible chronic pain = 12 to 15, probable chronic pain = 16 +) to form risk groups specific to the PROG-RES Study dataset provides groups with increasing levels of baseline pain intensity and depression and with expected proportions of people in each group with clinically significant pain at the 12-month follow-up (Table 3 ).
DISCUSSION
This study shows that the prognostic approach to define chronic pain, developed in a back pain sample by Von Korff and Miglioretti, 1 can be applied to predict the persistence of musculoskeletal pain in older adults consulting with musculoskeletal pain in a range of anatomic sites over a 12-month period. At baseline, a higher proportion of people was assigned to the intermediate risk group, and as a consequence, a lower proportion was seen in the probable chronic pain group than in previous studies using this methodology. 1, 4, 6 The prevalence of disabling pain was higher in the current sample than in the original population, but similar to the proportions found in previous British studies using this method. 4, 6 The ability of this Risk Score to distinguish between groups of patients with varying probabilities of continued significant pain over a number of time points suggests that the combination of factors that have previously been shown to predict the prognosis of pain at specific sites is also prognostic of pain in general, irrespective of the site of that pain. This provides evidence towards the suggestion of Von Korff and Dunn 3 that the Risk Score could provide a common metric for quantifying the severity and risk of pain. However, the analysis here did not aim to, and is unlikely to, provide optimal prediction of the presence of pain at follow-up as it was restricted to a small set of easily collected prognostic variables.
When applying the cut-points of Von Korff and Miglioretti 1 to the sample, the proportion of people continuing to have pain was higher than would be expected on the basis of the risk levels used to derive the original cutpoints. This may be because of the older age of the PROG-RES Study sample, as a similar phenomenon was seen in the knee pain sample of Thomas et al, 6 where the age of participants was similar to that in the PROG-RES Study. By applying the methods for the development of the cut-points in the original paper, 1 new cut-points were developed for the PROG-RES Study, which were found to be similar to new cutoffs derived by Thomas et al. 6 These new cut-points were higher than those suggested by Von Korff and Miglioretti 1 ; the cut-point for probable chronic pain in the current study was at approximately the same level as the cut-point for possible chronic pain in the original study. 1 As suggested previously, 1,4 a major limitation of the Risk Score is the timing of the collection of the prognostic indicators. It has previously been shown 14 that symptoms of pain decrease in the period immediately after consultation, and so the use of a questionnaire to collect prognostic information 2 to 6 weeks after consultation, as has been the case in studies utilizing this Risk Score so far, presents the question of whether the score is relevant to clinical practice. Further to this is the consideration of whether the individual variables required to calculate the Risk Score are collected in the same way in a GP consultation and in a research setting. For example, depression may be ascertained by the GP using a simple screening item, whereas in a research study, a multi-item, self-complete questionnaire might be used, as was the case in the current study with the use of the HADS. Furthermore, it is unclear whether different methods of data collection, such as faceto-face and anonymous questionnaires, result in different responses.
There was loss to follow-up in the PROG-RES Study cohort over the 12 months of follow-up. However, this is likely to have a minimal effect on the generalizability of the analyses performed in this paper, as the characteristics of the 2 groups, including baseline Risk Scores, were similar in those who were and were not followed up (data not shown).
The method of assessing the number of additional pain areas in the current study was different from that used in previous studies, because the "index" site of pain differed between patients in this study. Although this may be perceived as a weakness of the study, it should not be a cause for concern. Both Dunn et al 4 and Thomas et al 6 used an assessment of depression (HADS) different from that used by Von Korff and Miglioretti 1 (SCL-90-R) without apparent ill effects. Furthermore, the potential to interchange measures of each construct within the Risk Score widens the potential for its application in both research and practice, where different studies and clinical settings routinely use different assessments of the same constructs.
The performance of this Risk Score, developed in a younger LBP sample, among a group of older adults with a range of musculoskeletal pain conditions is encouraging, but the difference in cut-points for the score derived, empirically in this study, compared with those in the original study needs to be investigated further in larger samples. The higher levels of pain in this sample are likely responsible for this downward shift in cut-points, and other similar samples from groups of older adults are needed to externally assess the usefulness of the new cut-points derived from the PROG-RES Study data. In addition, the role of this Risk Score across anatomic sites in a younger sample should be investigated.
The Risk Score used in this paper included only the prognostic factors suggested by Von Korff and Miglioretti. 1 This is not an exhaustive group of prognostic factors for the chronicity of pain. For example, there is no measure of comorbidity (musculoskeletal or otherwise) and it may well be that the addition of anatomic site-specific pain indicators would improve the prognostic precision of the Risk Score in certain patients.
Further into the future, research might concentrate on the adaptation of this Risk Score, which is currently research oriented, into a practical tool for use in clinical practice, as it has been established that patients desire accurate information about their likely outcome. 2, 8 Many consultations, especially those with the GP, where a wholeperson view of the patient is assumed, already collect information on the prognostic indicators contained within the Risk Score. However, work may be required to convert the long-form prognostic indicators collected in research studies after the initial consultation into indicators that can be more easily administered in the consultation. The prognostic approach using this Risk Score needs to be shown to perform well in this context.
Furthermore, a recent randomized controlled trial of LBP presenting to primary care has shown that a stratified approach, through the use of prognostic screening with matched pathways, compared with usual care, can lead to improvements in clinical outcomes and reductions in costs. 15 The findings presented in the current paper suggest that taking a similar approach across anatomic pain sites might also lead to improved clinical and economic outcomes, provided appropriate matched treatment pathways can be found.
CONCLUSIONS
The prognostic approach to defining chronic pain, originally suggested by von Korff and Miglioretti 1 in a sample of back pain patients, is suitable for use in older adults consulting primary care with musculoskeletal pain at a range of sites. However, new cutoffs in the Risk Score are needed to allow for the higher risk profile in this older group. This holistic view of prognosis would blend well within a primary care setting, and as such, an adapted version of this method may have the potential for application directly within the clinical consultation in this setting.
